WuXi Biologics announced that it will increase the total manufacturing capacity of its facility in Worcester, Massachusetts to 36,000 liters. In response to global clients' increasing demand for contract manufacturing services, the Worcester facility, known as MFG11, will add 12,000 liters of commercial drug substance capacity, up from a planned 24,000 liters. Construction of the 189,500-square-foot facility is underway and recently achieved weather tight status.

The facility anticipates being operational in 2025 with GMP release in 2026. WuXi Biologics currently employs over 400 people in the U.S., and the Worcester facility will create an additional 200 new jobs when fully operational.